Home Tags Patritumab deruxtecan

Tag: patritumab deruxtecan

Merck & Co/MSD and Daiichi Sankyo to Jointly Development and Commercialization...

Merck & Co (known as MSD outside of the United States and Canada) and Daiichi Sankyo have entered into a global development and commercialization agreement for the jointly development of three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates.  The selected ADCs include patritumab deruxtecan (U3-1402/HER3-DXd), ifinatamab deruxtecan (DS-7300a/I-DXd) and raludotatug deruxtecan (DS-6000a/R-DXd).

Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients...

New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4 - 8, 2021, confirms promising...

Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs

With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as U3-1402), a HER3 directed DXd...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with to evaluate the combination of...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase...

Daiichi Sankyo and Gustave Roussy have signed a multi-year, multi-study research collaboration for the ongoing development of DS-1062 and patritumab deruxtecan (previously known as U3-1402),...

X